In an experimental FcR-dependent, Ab-mediated model of glomerulonephritis, administration of PF-06250112 (an oral BTK inhibitor) at the time of induction reduced proteinuria, supporting the role of inhibition of the BTK signaling pathway in limiting the disease development [83]. Here, BTK is linked to glomerulonephritis.